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Abstract
Background: Although enhanced priority-setting for investments in health research for development is essential to
tackling inequalities in global health, there is a lack of consensus on an optimal priority-setting process. In light of
the current surge in tuberculosis (TB) research investment, we use TB as a case study.
Methods: We investigated two critical aspects of a research prioritisation process, namely the criteria that should
be used to rank alternative research options and which stakeholders should be involved in priority-setting. We
conducted semi-structured interviews with 24 key informants purposively selected from four distinct groups –
academia, funding bodies, international policy or technical agencies, and national disease control programmes.
Interview transcripts were analysed verbatim using a framework approach. We also performed a systematic analysis
of seven diverse TB research prioritisation processes.
Results: There was consensus that well-defined and transparent criteria for assessing research options need to
be agreed at the outset of any prioritisation process. It was recommended that criteria should select for
research that is likely to have the greatest public health impact in affected countries rather than research that
mainly fills scientific knowledge gaps. Some interviewees expressed strong views about the need – and
reluctance – to make politically challenging decisions that place some research areas at a lower priority for
funding. The importance of taking input from stakeholders from countries with high disease burden was
emphasised; such stakeholders were notably absent from the majority of prioritisation processes we analysed.
Conclusions: This study indicated two critical areas for improvement of research prioritisation processes such
that inequalities in health are better addressed – the need to deprioritise some research areas to generate a
specific and meaningful list for investment, and greater involvement of experts working in high disease-
burden countries.
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Background
Every year, billions of dollars are invested in health re-
search and development, including new or improved
health products and processes [1, 2]. However, only a
small proportion of these funds addresses the health is-
sues that cause the greatest burden of disease, thereby
falling into the category of health research for develop-
ment (R4D) [3–5]. Thus, although investments in health
research have strengthened the evidence base to improve
policy setting and practice, health gains have not been
distributed equitably across population groups [6]. The
longstanding mismatch between health research that is
necessary to improve health in settings with the greatest
need, and that which funders invest in was first
highlighted in 1990 by the Commission on Health Re-
search for Development [5] – findings about the very
small proportion of global health research expenditure
directed toward diseases that have a large impact on
mortality in low- and middle-income countries became
known as the 90/10 gap [7]. Despite awareness of this
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issue, targeting research funding toward the health areas
with the greatest need for investment remains a critical
challenge [8].
Enhanced priority-setting for health R4D was therefore
identified by WHO and others as an essential part of the
solution to the persistent inequalities in global health
improvements [3, 9]. Priority-setting aims to increase
collaboration, coordination and overall investment,
directing funding toward research that will have max-
imum benefit to society [10]. While there is a clear need
to improve the process of R4D priority-setting, the def-
inition of an optimal process remains unclear. A number
of tools have been developed to address the gap and es-
tablish guidelines on research priority-setting, including
a module on deliberative priority-setting developed at
the Canadian Institutes of Health Research [12, 13].
However, an analysis of research priority-setting exer-
cises undertaken by WHO found that there is no gold
standard approach and that there is demand from pol-
icy-makers for normative work in this area [11]. For ex-
ample, while guidelines suggest that selecting who to
involve in determining priorities should be “inclusive”,
“transparent” and “strive for appropriate representation
of different expertise and for balanced gender and re-
gional participation”, guidelines are not clear about the
participation of stakeholders from for-profit organisa-
tions, high disease burden countries and sectors outside
health [14]. Similarly, the values or criteria that should
be used to assess and prioritise research areas are not
agreed across the range of groups conducting research
prioritisation since these can be subjective.
Tuberculosis (TB) provides an ideal case study owing
to the large number of stakeholders that have used alter-
native processes for TB research prioritisation [15], and
the surge in political and financial attention for TB re-
search following the first ever United Nations General
Assembly meeting on TB and the global Moscow declar-
ation to increase investment in TB [16, 17]. In recent
months, US$ 2 billion has been committed annually to
TB research. However, there has been criticism of how
effectively TB research money has been spent in the past
[18, 19] and effective ways of prioritising allocation of
this increased investment in TB research must be identi-
fied urgently [16].
Our study’s first objective was to investigate stake-
holder opinion on what an ideal R4D prioritisation
process might look like from diverse perspectives. In
particular, we focus on two contentious areas, namely
criteria that should be used to rank alternative research
priorities and which expert groups should be involved in
priority-setting decisions. The second objective was to
assess practices followed during existing TB R4D priority
processes in light of stakeholder opinions and guidelines
for prioritisation.
Methods
Study design
Based on Viergever et al.’s nine-item checklist for prior-
ity-setting [14], we identified components of the R4D
prioritisation process that were inherently subjective and
considered by the WHO team responsible for setting up
the Global Observatory on Health Research and Devel-
opment as being those for which normative guidance
was critical. We focused on two key components that
can have a major impact on the outcome of the priority-
setting process – (1) which criteria should be used to as-
sess and compare alternative research options for invest-
ment, and (2) which groups of experts should be
engaged as part of the prioritisation process.
We conducted a mixed methods study involving semi-
structured interviews and systematic analysis of seven
diverse TB R4D prioritisation processes.
Interviews
We designed a semi-structured topic guide to investigate
key informant perspectives on how an optimal R4D priori-
tisation process could be structured, focusing on the two
key questions detailed above. Twenty-four informants were
purposively selected to represent four distinct groups
whose views we sought to examine and compare, namely
academia (n = 9), funding bodies (n = 5), international pol-
icy or technical agencies (n = 6), and TB disease control
programmes in low- and middle-income countries (n = 4;
Afghanistan, Botswana, Pakistan and South Africa). Purpos-
ive selection was applied to ensure that we covered a range
of geographies, academic disciplines and sectors (non-
profit, for-profit) to capture diverse perspectives on health
R4D.
Semi-structured interviews were conducted by mem-
bers of the author team (all with MSc or PhD level qual-
ifications) with each of the informants in person or via
Skype. All authors had jointly designed the topic guide
and had expertise in TB. Interviews lasted between 20
and 45 min and were voice recorded with consent in all
cases, except for two informants who preferred to pro-
vide their thoughts as notes following the discussion.
Detailed notes were taken during the interviews.
All interviews were anonymised and assigned individ-
ual codes. Two of the researchers, one of whom was not
involved in conducting the interview, were responsible
for independently transcribing voice recorded interviews
verbatim. The framework method was used to facilitate
the manual analysis of transcripts and notes [19]. The
analysis began with an initial round of deductive coding
by a third researcher not involved in the transcription
process to minimise bias related to the researchers own
TB research interests, which included epidemiology, pol-
icy research and immunology. This was followed by a
round of inductive coding by all the authors to allow
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recurring themes to be identified. Attention was paid to
differences and similarities between views expressed by
different informants and we noted that data saturation
was reached with respect to views on the two questions
of focus outlined in the introduction.
Systematic analysis of existing TB R4D prioritisation
processes
To assess current practices with respect to R4D priori-
tisation and compare these with key informant views on
this, we analysed seven diverse R4D prioritisation pro-
cesses in terms of the criteria used to assess research op-
tions and the stakeholders involved. We used a two-step
method to identify TB R4D prioritisation processes for
comparison. In the first step, the authors screened peer-
reviewed and grey literature, and conducted an online
consultation with members of the London School of Hy-
giene and Tropical Medicine TB Centre, the WHO team
responsible for setting up the Global Observatory on
Health Research and Development, and the WHO Glo-
bal TB Programme. Based on the initial set of TB R4D
processes identified, we contacted leaders of each R4D
process to collect further information about their system
and to provide details about any other tools they were
aware of, using a snowballing methodology.
We identified 14 unique R4D prioritisation tools
or processes and included seven in our analysis that
had been used to prioritise between TB research in-
vestment options, with or without consideration of
other diseases in addition to TB (Table 1). Processes
that generated published recommendations and those
conducted by funding agencies that did not generate
publicly available recommendations were included
(for the latter, we contacted the organisation respon-
sible for conducting the process to collect relevant
data, and de-identified data before presenting it to
ensure the confidential information was not shared
outside the organisation).
Information about the criteria used to assess research
options and the stakeholders involved in each R4D pri-
oritisation process was extracted from published reports
or scientific papers, or by means of a structured discus-
sion with individuals responsible for leading the process
of interest, using a standardised data collection tool.
Information was captured in a standardised data capture
form to ensure that all questions were covered
adequately, and the use of multiple-choice answers facili-
tated standardised data collection across the seven R4D
prioritisation processes. Definitions used to classify the
different stakeholder groups and to classify the criteria
used for comparison during our analysis are presented
in Table 2. The same researcher extracted data about all
processes to ensure that a standardised approach was
applied, and at least one other researcher checked the
data extraction as a quality control measure.
Results
Overall, there was consensus among informants from
all four groups that the purpose of the prioritisation
exercise and, linked to this, the criteria used to assess
research options need to be clearly defined at the
outset. Informants believed that the remaining steps
in the process, including which stakeholders are in-
volved in making prioritisation decisions and what in-
formation should be presented to them, will follow
directly from these first decisions. However, infor-
mants recognised that making decisions about which
criteria to use and which stakeholders to involve can
be highly political, and will depend on the values and
strategic objectives of the organisation leading the pri-
oritisation process (A07).
Our detailed findings are structured according to the
two components of the R4D prioritisation process that
we focused on.
Selecting criteria to assess alternative R4D options
There was a strong sentiment, particularly among fund-
ing body representatives, that the criteria or values used
to prioritise R4D options for investment are neither clear
nor specific enough (F02, F04, F05, A07). These infor-
mants thought that the purpose – for example, to maxi-
mise benefit to the affected populations or, alternatively,
to reduce inequalities in health – should be linked to
clearly articulated criteria that act as the basis for pri-
oritisation decisions. However, it was also recognised
that it is politically challenging for an organisation,
such as WHO, to take a strong position on which
criteria (and therefore which research areas) are most
important, for example, deciding between cost-effect-
iveness and equity impact of research investments,
which are at times mutually exclusive.
Table 1 Research for development prioritisation processes
analysed
Name of process Owner
Internal Prioritization Assessment Private for-profit
Special Programme for Research and
Training in Tropical Diseases
WHO
International Roadmap for TB Research WHO
Priorities for TB Research: A Systematic
Review
Study authors
TB Program Strategy Private non-profit
Vaccine Research and Development
Prioritisation
Private non-profit
Research and Development Funding Gaps
Analysis
Government research
agency
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Elaborating on this point, a funding agency em-
ployee (F05) asserted that research prioritisation lists
published by WHO are less useful than they could
be, possibly doing more harm than good in terms of
attracting interest from funding bodies because they
appear to capture everything as a priority, without
sufficient narrowing down or de-prioritisation.
“I’ve seen recently enough WHO people make intents
to do something like…a global TB research agenda.
Then they come up and say it’s going to cost US$ 4
billion, and to me that’s absolutely not helpful, that’s
not helpful at all. There's something about boiling the
ocean about it, when I’m hearing… a certain project
could cost US$ 25 million or US$ 100 million, yes we
can talk about this. When it’s US$ 6 billion, then …
there's nothing I can do about that and it scares
people away.. I think it actually backfires. So I don't
believe in grand schemes to be honest...” (F04)
In terms of the number of criteria that should be used,
all informants were comfortable selecting three or four
criteria on the basis of which they believed R4D options
should be ranked. One international policy-maker
(IP03), with extensive experience of prioritisation exer-
cises, stressed that multiple criteria (three to five) should
be adopted to rank options as one criterion is not suffi-
cient. On the other hand, it was consistently recognised
that too many criteria make the processes overly lengthy
and complicated for participants, and that important
conversations about criteria and values might be difficult
as trade-offs need to be made, including de-prioritising
some research areas owing to a lack of resources.
Effectiveness/efficacy and deliverability at scale within
high disease-burden settings were the two criteria con-
sidered most important by the majority of informants,
who reasoned that these two criteria contribute to the
impact of research, which they perceived to be the key
aim of investments. Several of the academics interviewed
felt that impact on disease control was more important
than simply addressing knowledge gaps, or minimising
costs, or sustainability (A02, A03, A05).
“I think effectiveness is certainly the most important,
there’s no point having something that is deliverable
and equitable and sustainable if it’s not effective, so I
think the entry point is having something that is
effective… Knowledge gaps, less so, less so, I think it’s
primarily about identifying things that are likely to
have a big impact, and working out whether or not
you can deliver them at scale, and the cost will
eventually take care of itself if it’s a good enough
intervention.” (A02)
Academics differed in opinion on the meaning of ef-
fectiveness, with one defining it in terms of lives saved
over a 15-year period (A07) and another stressing that
effectiveness should be thought of in terms of impact on
the quality of life of affected people and not just in terms
of deaths or new cases averted (A01). Other academics
(A04, A09) and a funding agency employee (F05), how-
ever, considered cost-effectiveness to be the most
important criterion for prioritising R4D options. In con-
trast, some programme managers from low- and middle-
income countries (NP01, NP02) felt that sustainability,
in terms of the availability of resources locally to imple-
ment any new intervention that is developed, is critical
along with effectiveness:
Table 2 Standardised tool used to collect information about
the processes
Tool component Standard definition used to determine which
stakeholders and criteria were relevant
Which stakeholders were
involved as experts?
[tick all that apply]
• Academics
o From a single discipline such as one of:
basic science, epidemiology, operational/
translational research, health economics,
health policy and systems research, etc.
o From multiple disciplines: two or more
disciplines
• International policy-makers/technical
experts: representatives of WHO and other
policy or technical assistance bodies
working across multiple countries
• National disease control programme
representatives
• Civil society: advocacy groups, community
groups, etc.
• Funding body representatives: Funding
Gaps Analysis, TB Program Strategy,
Wellcome Trust, etc.
• Patients
• Physicians: whose primary occupation is
treating (TB) patients in high-burden
settings
• Industry representatives or product
development partnerships
What criteria/values were
used to prioritise
areas? [tick all that apply]
• Effectiveness/efficacy: impact on reducing
disease burden or adverse consequences of
disease
• Knowledge gap: addressing critical scientific
knowledge gaps that limit progress on
disease control
• Cost-effectiveness: cost of delivery relative
to impact is appropriate for high disease-
burden settings
• Deliverability: investment will produce an
output that can be implemented and
deliver impact in settings with high disease
burden (feasibility)
• Equity: knowledge or tool produced will
benefit all populations, including vulnerable
groups and populations in low-resource
settings
• Sustainability: output implementation can
be supported by finances and infrastructure
available in high disease burden settings for
the long term
• Other (specified)
Khan et al. Health Research Policy and Systems           (2019) 17:68 Page 4 of 9
“I think for programmes, sustainability is very important,
because what will happen when donors will go away? We
are dependent 95% on donors now, so what will happen
in future…and then obviously effectiveness is very
important. Equity, yes, but I would still rank
sustainability and effectiveness on top.” (NP02)
A number of informants from different groups empha-
sised that deliverability needs to be assessed early, or in
parallel, with effectiveness (IP01, NP02). There was rec-
ognition that, in the past, considerations about deliver-
ability in resource-constrained health systems have been
left until too late.
“You’ve got to do your efficacy work, but don’t wait 4
years… let’s also run parallel effectiveness studies,
[and] deliverability scale up, let’s try and get that
evidence working together. I’m not sure people think
like that.” (IP01)
Related to this point, another frequent suggestion from
the academics, funding agency employees and inter-
national policy-makers was that evaluation of past in-
vestments to assess real impact achieved (as opposed to
projected impact) is critical to consider, although such
information is rarely provided to inform prioritisation
decisions.
“We are interested in whatever we have done, how
much is (achieving) good impact.” (NP02)
Our analysis indicated that a perceived advantage of
assessing actual impact retrospectively is that health sys-
tems constraints in delivery are accounted for:
“But I would want that exercise to be grounded in
reality, so to take the data we have now for TB or HIV
resource tracking and start from looking historically at
the investments and what they yielded and try to
come up with some kind of relationship there, rather
than think about it prospectively, which is too subject
to vague expert opinion.” (IP07)
Our analysis of how a range of prioritisation processes
have been run showed that the majority (5/7) assessed
research options against five or more criteria (Fig. 1).
The ‘Internal Prioritization Assessment’ process included
the highest number of criteria, while the ‘Priorities for
TB Research: A Systematic Review’ and ‘TB Program
Strategy’ processes included the lowest, two and three,
respectively. In keeping with its purpose, the ‘Priorities
for TB Research: a Systematic Review’ prioritised re-
search options using knowledge gaps identified by the
researchers as a key criterion, and additionally consid-
ered research priority areas highlighted in other publica-
tions. The most frequently used criteria among the
prioritisation processes were effectiveness and/or efficacy
(6/7) – which is consistent with key informant opinions
– and knowledge gaps (6/7), followed by deliverability
(5/7), equity (4/7), cost-effectiveness and sustainability
(3/7). Additional criteria used in individual processes led
by commercial or non-profit bodies with their own fund-
ing included manufacturability (Internal Prioritization As-
sessment) or business case (Vaccine Research and
Development Prioritisation). The two processes run by
groups within WHO – the Special Programme for Re-
search and Training in Tropical Diseases and the Inter-
national Roadmap for TB Research (Roadmap) –
additionally considered alignment of alternative research
TDR Roadmap SR TPS IPA Vaccine FGA
Prioritisation processes
Others
Sustainability
Equity
Deliverability
Cost-effectiveness
Knowledge gap
Effectiveness and/or efficacy
Fig. 1 What criteria were used to prioritise? TDR Special Programme for Research and Training in Tropical Diseases; Roadmap International
Roadmap for TB Research; SR Priorities for TB Research: A Systematic Review; TPS TB Program Strategy; IPA Internal Prioritization Assessment;
Vaccine Vaccine Research and Development Prioritisation; FGA Research and Development Funding Gaps Analysis
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areas to global goals (such as the Sustainable Development
Goals), and whether research would bring about health
gains in an ethical way while minimising potential harm
to patients.
Experts to be engaged in research priority-setting
exercises
A common theme emerging from interviews was that en-
gaging a broad range of stakeholders in prioritisation exer-
cises is essential, with several informants (12/24)
emphasising that it is critical to include stakeholders
working on the ground in high disease burden countries.
Stakeholders with ‘in-country’ or ‘front-line’ expertise who
were identified as important to involve included national
programme representatives, academics or researchers (dis-
ease specific and non-specific), and programme imple-
menters. One government (health) programme manager
and lead researcher (NP02) held the view that research of-
ficers in national programmes, as well as the managers,
should be involved as they often have greater insight into
prioritising research areas. In line with these suggestions,
one funding agency employee felt strongly that prioritisa-
tion processes should avoid involving a small group of ex-
perts exclusively and repeatedly, which makes the process
“incestuous” (F04). A second funding agency employee il-
lustrated the pitfalls of failing to include those stake-
holders who will ultimately be responsible for using any
new tools or interventions developed in relation to TB
control:
“…to what degree do we really engage the ultimate
demand stakeholders, which are, at the end of the day,
the patient, the healthcare workers and the country
decision-makers in this kind of development of future
interventions? My gut feeling is that the lion’s share of
the conversation is what can we do, from our analysis
that we think would be helpful, and I don’t think we
do enough of a job balancing that with a deep
conversation with the country’s national TB control
coordinators themselves…” (F05)
There were mixed views about whether funding
body representatives, particularly those from industry,
should be involved in any ranking or voting process.
Funders’ involvement for buy-in was considered im-
portant by a range of informants (NP02, IP07, IP08,
F11, A03, A07, A08), but some academics (A05, A06,
A09) raised concerns about involving companies that
may have a commercial interest in specific research
options being prioritised:
“..so I guess I’d be quite happy for impartial research
funders to be there, but maybe research funders linked
to industry, I would have to be cautious about, and I
guess it raises a broader question, which I’ve also
hinted at before, the process whereby stakeholders are
selected and conflicts of interest are put on the table
and managed, I think that needs to be part of that
process, it’s not just about who but how, how they’re
engaged.” (A09)
When probed about the appropriateness of them
being represented in priority-setting, some funding
agency employees and industry representatives com-
mented that excluding them from processes owing
to conflicts of interest is unwarranted since aca-
demics and other stakeholders may also have per-
sonal preferences that shape their views.
There were also diverging views on the involvement of
civil society representatives and patients. While the im-
portance of involving affected people was generally
agreed upon, there were questions about how to best
represent patients (A07).
Systematically comparing the number and types of stake-
holder groups involved in determining priorities in each of
the seven processes revealed substantial variations in prac-
tice (Fig. 2). Academics (multiple disciplines), funders and
technical experts/international policy-makers were most
frequently involved; five of the seven processes engaged
representatives from these stakeholder groups. In stark con-
trast to the strongest recommendation from key infor-
mants, only one of the seven processes (Roadmap) involved
representatives from National Disease Control Programmes
and civil society groups. The Roadmap prioritisation
process led by WHO engaged the highest number of stake-
holders to decide on priorities, excluding only single discip-
line academics. However, the Special Programme for
Research and Training in Tropical Diseases process, also
led by a group within WHO, only engaged academics
(multi-discipline) to advise on priorities, which was the low-
est number of stakeholders among the compared processes.
None of the processes involved TB patients or physicians
treating TB.
Discussion
Commitment to operationalise and strengthen R4D pri-
oritisation processes has been expressed at the highest
levels, most recently at the 2016 World Health Assembly
[20]. A critical barrier to this has been the lack of con-
sensus and normative research on two critical compo-
nents of a R4D prioritisation process – which criteria
should be applied to prioritise between alternative re-
search options and which groups of experts should be
engaged [9]. Our study, which is the first to address
these questions through a qualitative investigation of
views from diverse informants and a systematic analysis
of practices adopted in a range of existing TB R4D pri-
oritisation processes, revealed that R4D prioritisation
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processes could be improved by involving stakeholders
with expertise of high disease burden settings; only one
of the processes analysed involved TB programme staff
from affected countries and none included frontline
healthcare providers. In terms of criteria used for priori-
tisation, the majority of processes included effectiveness
(for impact on TB), which was a key criterion suggested
by the majority of informants. However, we found that
R4D prioritisation processes typically assessed research
areas in terms of the extent to which they addressed a
scientific knowledge gap, and this was not perceived to
be as important by informants.
Irrespective of which criteria are chosen, trade-offs be-
tween different criteria and politically challenging deci-
sions on the values of most importance to the WHO (or
other priority-setting agency) were seen as being essen-
tial in order to generate a more specific and meaningful
list of research priorities. There were strong views
among some funding agency employees in particular
that failure to do this has resulted in prioritisation pro-
cesses producing research investment lists that cover too
many research options, presenting unrealistically large
budgets for funders to respond to.
In relation to the question about which stakeholders
should be engaged as part of the prioritisation process, it
was recognised by several informants that all stake-
holders involved in an R4D prioritisation exercise (in-
cluding academics) may have some degree of bias or
personal interest in supporting specific research areas,
and that an unbiased ranking of R4D options may not
be possible or even useful. Indeed, in line with the views
of informants interviewed, studies have shown that dif-
ferent stakeholder groups prioritise research options dif-
ferently [21, 22]. In light of the variation in stakeholder
perspectives, a specific recommendation emerging was
to ensure inclusion of stakeholders working at the policy
or service delivery level in countries with a high disease
burden. However, our analysis of prioritisation processes
showed that academics and funders were represented
commonly, whereas voices from policy-makers and
practitioners in affected countries were not, and a poten-
tial danger of excluding these groups, raised by infor-
mants, was that the prioritisation process may result in
the deliverability and acceptability of research options
being less thoroughly considered. Furthermore, engage-
ment of policy-makers and users of research in shaping
and conducting the studies that are funded is closely
related to action of research findings, as demonstrated
in a study by Kok et al. [23]. In line with this con-
cern, a recent analysis found that TB research con-
ducted in Cambodia aligns poorly with domestic
policy-makers’ priorities [24], and our findings may
reflect a wider issue related to global agendas for
health research being poorly aligned with local needs
[25]. Although the recommendation to increase the
number of stakeholders involved in prioritisation pro-
cesses appears straightforward, we acknowledge the
challenges in finding a balance between productivity
(agreeing on a relatively small list of research prior-
ities in the time available) and inclusion (including all
voices and perspectives).
A limitation of our study is that we only analysed the
views of a limited number of key informants, and we ac-
knowledge that our scope excluded views of groups such
as patients, healthcare providers, health system adminis-
trators and politicians. To investigate an important
recurring theme about the impact of R4D prioritisation
processes on shaping investments in research being lim-
ited because research lists produced are too broad or be-
cause prioritisation processes do not sufficiently take
health systems constraints into account, we suggest
objectively evaluating the impact of research prioritisa-
tion exercises. With increasingly more investment in im-
proved, transparent processes and data for research
prioritisation, it is important to evaluate whether priori-
tisation exercises have resulted in changes to investment
in research areas in line with recommendations [26]. Since
the majority of grants awarded to undertake research
within prioritised research areas (for example, TB case
finding) are allocated following a process of peer-review
TDR Roadmap SR TPS IPA Vaccine FGA
Prioritisation processes
Others
Funders
Civil society
Technical experts & international policy makers
National Programme representatives
Multi-discipline academics
Single discipline academics
Fig. 2 Who was involved in priority-setting?
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and rating by academics, it may be that academics end up
acting as gatekeepers that can ultimately shift funding to-
wards studies that primarily address knowledge gaps ra-
ther than those that generate findings with practical utility
for affected populations. Several global health research
priority-setting exercises have been conducted since the
late 1990s and an assessment of their impact would indi-
cate whether these are useful to funders and implementers
[26–28]. Assessing impact of research prioritisation exer-
cises is not straightforward, and the first step would
involve defining appropriate indicators. Suggested indica-
tors, such as changes in research output and in funding
flows toward research based on the established research
priorities, would be useful but complicated to track and
compare across countries [11, 29]. The indicators would
also stop short of assessing impact on health, since they
focus on whether research priorities have changed, but
not whether the prioritisation exercises result in changes
to how funds are allocated to research.
Conclusions
Decisions on prioritisation criteria and expert engagement
are critical not only to the R4D prioritisation processes out-
comes in terms of a recommended research priority list, but
also to indicate how useful and widely accepted the recom-
mendations are. We highlight three important findings
emerging from this study that may help to inform develop-
ment of enhanced R4D prioritisation processes for TB and
other diseases. Firstly, although it may be politically challen-
ging, some research areas must be deprioritised in order to
generate useful recommendations from a prioritisation exer-
cise, and this should be done on the basis of multiple, clearly
articulated criteria for comparing R4D options. Secondly,
there should be more attention to the health systems in
which research outputs are to be implemented as part of
prioritisation exercises. This may be achieved by increased
involvement of policy-makers and implementers from high
disease-burden countries, which is currently lacking. Finally,
it should be recognised that no group of experts – including
funders and academics – are entirely unbiased in their as-
sessments of research options; all could potentially have
vested interests in the outcome of the prioritisation exercise.
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